If you liked this article you might like

Analysts' Actions -- FireEye, Kraft, Teva, U.S. Steel and More
Akorn (AKRX) Stock Drops Despite Q2 Beat
Pricing Stress may Weigh on Generic Drugmakers Ahead of Q2 Earnings
Analysts Differ On Impact Of Valeant's Rejected Takeover Bid